About: ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
Creator	Catanese, Silvia Douillard, Jean-Yves Lordick, Florian Pentheroudakis, George
Source	Medline; PMC; WHO
abstract	The COVID-19 pandemic is challenging the capacities of health systems in many countries. National healthcare services have to manage unexpected shortages of healthcare resources that have to be re-allocated according to the principles of fair and ethical prioritisation, in order to maintain the highest levels of care to all patients, ensure the safety of patients and healthcare workers, and save as many lives as possible. Also, cancer care services have to pursue restructuring, following the same evidence-based dispositions. In this article, we propose a guidance to the management of pancreatic cancer during the pandemic, prioritised according to a three-tiered framework, and based on expert clinical judgement and magnitude of benefit expected from specific interventions. Since the availability of resources for diagnostic procedures, surgery and postoperative care, systemic therapy and radiotherapy may differ, the authors have separated the prioritisation analyses. The impact of postponing or abrogating cancer interventions on outcomes according to a high, medium or low priority scale is outlined and discussed. The implementation of healthcare services using telemedicine is explored; it reveals itself as functional and effective for limiting patients’ need to travel to centres and thereby has the potential to reduce diffusion of SARS-CoV-2. Pancreatic cancer demands a considerable amount of medical resources. Therefore, the redefinition of its diagnostic and therapeutic algorithms with a rigorous method is crucial in order to ensure the highest quality of continuum of care in the broader context of the pandemic and the challenged healthcare systems.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1136/esmoopen-2020-000804
bibo:pmid	32423899
has license	cc-by-nc
sha1sum (hex)	e903175f5cd2c5fbcb735b6f25e184952d16c20d
schema:url	https://doi.org/10.1136/esmoopen-2020-000804
resource representing a document's title	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
has PubMed Central identifier	PMC7239531
has PubMed identifier	32423899
schema:publication	ESMO Open
resource representing a document's body	covid:e903175f5cd2c5fbcb735b6f25e184952d16c20d#body_text
is schema:about of	named entity 'era' named entity 'corticosteroids' named entity 'pancreatic cancer' named entity 'adjuvant' named entity 'life-threatening' named entity 'tumour' named entity 'adaptative' named entity 'medical emergency' named entity 'supportive care' named entity 'oncological' named entity 'cancer treatment' named entity 'COVID-19 pandemic' named entity 'diagnostic tests' named entity 'pain relievers' named entity 'healthcare systems' named entity 'national health' named entity 'metastatic' named entity 'thromboembolism' named entity 'healthcare professionals' named entity 'COVID-19' named entity 'healthcare systems' named entity 'radiotherapy' named entity 'cancer care' named entity 'pancreatic cancer' named entity 'SARS-CoV-2' named entity 'viral infection' named entity 'palliative treatments' named entity 'psychological support' named entity 'telemedicine' named entity 'MCBS' named entity 'telemedicine' named entity 'chemotherapy treatment' named entity 'major surgery' named entity 'oncologists' named entity 'pancreatic cancer' named entity 'comorbidities' named entity 'healthcare professionals' named entity 'telemedicine' named entity 'mortality rate' named entity 'tumour' named entity 'spleen' named entity 'SARS-CoV-2' named entity 'palliation' named entity 'adjuvant treatment' named entity 'COVID-19 pandemic' named entity 'Tumour' named entity 'pancreatic cancer' named entity 'adverse events' named entity 'performance status' named entity 'pros and cons' named entity 'hypercalcaemia' named entity 'physical examination' named entity 'healthcare facilities' named entity 'ICU' named entity 'WHO' named entity 'COVID-19 pandemic' named entity 'covid-19' named entity 'comorbidities' named entity 'morbidity' named entity 'COVID-19 pandemic' named entity 'risk of death' named entity 'SARS-CoV-2' named entity 'palliative' named entity 'premedication' named entity 'anti-inflammatory' named entity 'cholangitis' named entity 'adjuvant chemotherapy' named entity 'SARS-CoV-2' named entity 'older age' named entity 'follow-up' named entity 'gastrointestinal' named entity 'adverse events' named entity 'ICU' named entity 'infection' named entity 'infection' named entity 'pancreatic cancer' named entity 'prophylaxis' named entity 'thromboembolic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software